Novocure Reports Presentation Of Clinical Data From Phase 3 METIS Trial; Says Trial Met Its Primary Endpoint, Demonstrating Statistically Significant Improvement In Time To Intracranial Progression
Portfolio Pulse from Benzinga Newsdesk
Novocure reported positive clinical data from its Phase 3 METIS trial, showing that its TTFields therapy significantly improved the time to intracranial progression in patients compared to best standard care alone.
June 03, 2024 | 12:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Novocure's Phase 3 METIS trial met its primary endpoint, demonstrating a statistically significant improvement in time to intracranial progression for patients treated with TTFields therapy compared to best standard care alone.
The successful results from the Phase 3 METIS trial are likely to boost investor confidence in Novocure's TTFields therapy, potentially leading to a positive short-term impact on NVCR's stock price. The statistically significant improvement in time to intracranial progression is a strong indicator of the therapy's efficacy.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100